These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 7729742)

  • 1. Tumor marker trends in asymptomatic women at risk for ovarian cancer: relevance for ovarian cancer screening.
    Cane P; Azen C; Lopez E; Platt LD; Karlan BY
    Gynecol Oncol; 1995 May; 57(2):240-5. PubMed ID: 7729742
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ovarian cancer tumor marker behavior in asymptomatic healthy women: implications for screening.
    Crump C; McIntosh MW; Urban N; Anderson G; Karlan BY
    Cancer Epidemiol Biomarkers Prev; 2000 Oct; 9(10):1107-11. PubMed ID: 11045795
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
    Piver MS
    Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Calculation of the risk of ovarian cancer from serial CA-125 values for preclinical detection in postmenopausal women.
    Skates SJ; Menon U; MacDonald N; Rosenthal AN; Oram DH; Knapp RC; Jacobs IJ
    J Clin Oncol; 2003 May; 21(10 Suppl):206s-210s. PubMed ID: 12743136
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer.
    Baron AT; Boardman CH; Lafky JM; Rademaker A; Liu D; Fishman DA; Podratz KC; Maihle NJ
    Cancer Epidemiol Biomarkers Prev; 2005 Feb; 14(2):306-18. PubMed ID: 15734951
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Strategies for improving the specificity of screening for ovarian cancer with tumor-associated antigens CA 125, CA 15-3, and TAG 72.3.
    Jacobs IJ; Oram DH; Bast RC
    Obstet Gynecol; 1992 Sep; 80(3 Pt 1):396-9. PubMed ID: 1495694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum CA-125 in relation to adnexal dysplasia and cancer in women at hereditary high risk of ovarian cancer.
    Hermsen BB; von Mensdorff-Pouilly S; Berkhof J; van Diest PJ; Gille JJ; Menko FH; Blankenstein MA; Kenemans P; Verheijen RH
    J Clin Oncol; 2007 Apr; 25(11):1383-9. PubMed ID: 17416858
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma lipid-associated sialic acid and serum CA 125 as indicators of disease status with advanced ovarian cancer.
    Vardi JR; Tadros GH; Foemmel R; Shebes M
    Obstet Gynecol; 1989 Sep; 74(3 Pt 1):379-83. PubMed ID: 2761915
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proteomic tracking of serum protein isoforms as screening biomarkers of ovarian cancer.
    Ahmed N; Oliva KT; Barker G; Hoffmann P; Reeve S; Smith IA; Quinn MA; Rice GE
    Proteomics; 2005 Nov; 5(17):4625-36. PubMed ID: 16220531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic markers for early detection of ovarian cancer.
    Visintin I; Feng Z; Longton G; Ward DC; Alvero AB; Lai Y; Tenthorey J; Leiser A; Flores-Saaib R; Yu H; Azori M; Rutherford T; Schwartz PE; Mor G
    Clin Cancer Res; 2008 Feb; 14(4):1065-72. PubMed ID: 18258665
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Significance of a single CA 125 assay combined with ultrasound in the early detection of ovarian and endometrial cancer.
    Vuento MH; Stenman UH; Pirhonen JP; Mäkinen JI; Laippala PJ; Salmi TA
    Gynecol Oncol; 1997 Jan; 64(1):141-6. PubMed ID: 8995563
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Serum lipid-associated sialic acid (LSA) in diagnosing and monitoring ovarian cancer].
    Yue K; Bian M; Zhu D; Liu W; Siu S
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1995 Apr; 17(2):128-32. PubMed ID: 7656393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of biological variation and analytical imprecision of CA 125, CEA, and TPA in relation to monitoring of ovarian cancer.
    Tuxen MK; Sölétormos G; Petersen PH; Schioler V; Dombernowsky P
    Gynecol Oncol; 1999 Jul; 74(1):12-22. PubMed ID: 10385546
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preoperative serum tetranectin, CA125 and menopausal status used as single markers in screening and in a risk assessment index (RAI) in discriminating between benign and malignant ovarian tumors.
    Begum FD; Høgdall E; Kjaer SK; Blaakaer J; Christensen IJ; Christensen L; Høgdall C
    Gynecol Oncol; 2009 May; 113(2):221-7. PubMed ID: 19261323
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipid associated sialic acid in plasma in patients with advanced carcinoma of the ovaries.
    Vardi JR; Tadros GH; Malhotra C; Charney T; Shebes M; Foemmel R
    Surg Gynecol Obstet; 1989 Apr; 168(4):296-301. PubMed ID: 2928903
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary and metastatic ovarian cancer in patients with prior breast carcinoma. Pre-operative markers and treatment results.
    Tserkezoglou A; Kontou S; Hadjieleftheriou G; Apostolikas N; Vassilomanolakis M; Sikiotis K; Salamalekis E; Tseke P; Magiakos G
    Anticancer Res; 2006; 26(3B):2339-44. PubMed ID: 16821613
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CA 125, NB/70K, and lipid-associated sialic acid in monitoring uterine papillary serous carcinoma.
    Tseng PC; Sprance HE; Carcangiu ML; Chambers JT; Schwartz PE
    Obstet Gynecol; 1989 Sep; 74(3 Pt 1):384-7. PubMed ID: 2761916
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Breast cancer and family history: levels of lipid-associated sialic acid in plasma and absent family history of breast cancer in women who have breast tumors.
    Brower ST; Tartter P; Weiss S; Luderer AA; Lehrer S
    Mt Sinai J Med; 1995 Nov; 62(6):419-21. PubMed ID: 8692154
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship of serum levels of tumor markers with tissue expression of gene products in ovarian carcinoma.
    Sorak M; Arsenijević S; Lukić G; Arsenijević N; Ristić P; Pavlović S; Popović S; Baskić D
    J BUON; 2007; 12(1):99-104. PubMed ID: 17436409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CASA and Ca 125 in diagnosis and follow-up of advanced ovarian cancer.
    Oehler MK; Sütterlin M; Caffier H
    Anticancer Res; 1999; 19(4A):2513-8. PubMed ID: 10470185
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.